Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.

Sara M TolaneyYoung-Hyuck ImEmiliano CalvoYen-Shen LuErika HamiltonAndres Forero-TorresThomas BachelotMichela MaurAngelica FasoloRalph TiedtLisa NardiUz StammbergerAhmed M AbdelhadyShiling RuanSoo Chin Lee

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Ribociclib plus fulvestrant demonstrated safety in the treatment of patients with HR+, HER2- ABC. Triple combinations with alpelisib or buparlisib plus fulvestrant are not recommended for phase II investigation.See related commentary by Clark et al., p. 371.

Keyphrases

metastatic breast cancer
phase ii
clinical trial
open label
phase iii
young adults
combination therapy
replacement therapy
study protocol